Dosing, Safety, and Tolerability of Extended‐Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients
Pediatric Transplantation · 2026-05 · 30 (5)
DOI: 10.1111/petr.70349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 23.05.2026. Verfasst von Terry Dang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Postdoctoral Training Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Tacrolimus, Immunosuppressive Agents, Organ Transplantation, Graft Rejection. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Veloxis Pharmaceuticals, NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Background
Complicated immunosuppression regimens can contribute to non‐adherence in pediatric solid organ transplant (SOT) recipients. Once‐daily tacrolimus formulations, such as LCP‐tacrolimus (LCPT), may help simplify dosing, but pediatric data on dosing, safety, and early tolerability are limited.
Methods
We conducted a single center retrospective cohort study of SOT recipients prescribed LCPT from December 2016 to July 2024 at our institution. LCPT:IR‐Tac daily dosing ratios were calculated. The frequency of laboratory‐associated adverse events (AE) and of new patient‐reported adverse events in the first 90 days were collected and compared across pediatric‐ and adult‐aged SOT recipients.
Results
Ninety‐one SOT recipients were prescribed LCPT at a median age of 16.8 years (range 8.4–24.1) and 75 months after transplant (range 0.25–217). Among 53 patients who were therapeutic on both IR‐Tac and LCPT, the median daily dosing ratio of LCPT:IR‐Tac was 0.75 (range 0.33–1.5) for pediatric patients and 0.75 (IQR: 0.46–1.33) for adults. Eleven (5 patient‐reported and 6 laboratory) AEs were identified, none of which resulted in cessation of LCPT therapy. There were no significant differences in the frequency of AEs between children and adults.
Conclusions
LCPT was well tolerated and typically required about a 25% dose reduction compared with IR‐tacrolimus, though conversion ratios varied widely. These findings offer practical guidance for LCPT dosing in pediatric transplant care and highlight the need for individualized titration and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Postdoctoral Training Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Terry Dang, Jennifer Hewlett, John McAteer, Kevin J Downes
Förderung
- Veloxis Pharmaceuticals
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Dang, T., Hewlett, J., McAteer, J., & Downes, K. J. (2026). Dosing, Safety, and Tolerability of Extended‐Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients. Pediatric Transplantation, 30(5). https://doi.org/10.1111/petr.70349
Vancouver
Dang T, Hewlett J, McAteer J, Downes KJ. Dosing, Safety, and Tolerability of Extended‐Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients. Pediatric Transplantation. 2026;30(5). doi:10.1111/petr.70349
BibTeX
@article{Dang2026,
author = {Dang, Terry and Hewlett, Jennifer and McAteer, John and Downes, Kevin J},
title = {Dosing, Safety, and Tolerability of Extended‐Release Tacrolimus in Pediatric and Young Adult Solid Organ Transplant Recipients},
journal = {Pediatric Transplantation},
year = {2026},
volume = {30},
number = {5},
doi = {10.1111/petr.70349}
}
EUVIMED